More Than 450 Companies Drive Speed
to Market with ³Ô¹Ï±¬ÁÏ RIM
Advanced regulatory capabilities and new industry partnerships accelerate collaboration with global health authorities
BARCELONA, Spain ¡ª 2 Sept. 2025 ¡ª ³Ô¹Ï±¬ÁÏ Systems (NYSE: VEEV) today announced more than 450 companies, including 19 of the top 20 biopharmas, have adopted ³Ô¹Ï±¬ÁÏ RIM for regulatory information management (RIM) on a unified platform. Continued innovation to advance connectivity now includes partnerships with and , enabling integration with multi-health authority platforms to drive efficiency and compliance.
¡°Regulatory teams are adopting new ³Ô¹Ï±¬ÁÏ product innovations to continually improve efficiency and reduce cycle times. Strengthened by industry partnerships, ³Ô¹Ï±¬ÁÏ RIM provides an end-to-end solution that accelerates time to market, improves global stakeholder collaboration, and enables seamless data flow in a rapidly evolving regulatory environment,¡± said Marc Gabriel, vice president, regulatory at ³Ô¹Ï±¬ÁÏ.
Companies using ³Ô¹Ï±¬ÁÏ RIM applications can streamline processes across all steps of the regulatory lifecycle. With ³Ô¹Ï±¬ÁÏ Submissions Publishing, more than 85 organizations are using continuous publishing to reduce rework and remove bottlenecks, accelerating submission timelines.
¡°Our strategic partnership will connect the Accumulus platform and ³Ô¹Ï±¬ÁÏ RIM for greater interoperability to modernize how information is instantly and simultaneously shared with our growing network of over 70 regulatory agencies worldwide. By facilitating seamless regulatory submissions, we can empower our mutual customers to get treatments to patients faster,¡± said Francisco Nogueira, CEO of Accumulus Technologies.
¡°Integrating DNAnexus Trusted Regulatory Spaces (TRS) and ³Ô¹Ï±¬ÁÏ RIM will provide best-in-class data sharing capabilities for inter-agency collaboration and faster regulated product approvals,¡± said Thomas Laur, CEO of DNAnexus.
³Ô¹Ï±¬ÁÏ RIM streamlines global regulatory processes on a single, cloud-based platform. It is part of ³Ô¹Ï±¬ÁÏ Development Cloud, the technology foundation for product development across clinical, quality, regulatory, and safety. To learn more about ³Ô¹Ï±¬ÁÏ RIM, visit veeva.com/eu/RIM.
About ³Ô¹Ï±¬ÁÏ Systems
³Ô¹Ï±¬ÁÏ delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 1,500 customers, ranging from the world¡¯s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, ³Ô¹Ï±¬ÁÏ is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.
³Ô¹Ï±¬ÁÏ Forward-Looking Statements
This release contains forward-looking statements regarding ³Ô¹Ï±¬ÁÏ¡¯s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2025, which you can find (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at .
###
Contact:
Jeremy Whittaker
³Ô¹Ï±¬ÁÏ Systems
+49-695-095-5486
jeremy.whittaker@veeva.com